Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

App helps men at risk for HIV test themselves and get linked to care

NCT ID NCT05484895

Prevention Sponsor: Emory University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a mobile app called WeTest-WeLink to help high-risk men in China test themselves for HIV and connect to care. 1,800 HIV-negative men who have sex with men used the app or received standard information. The goal was to see if the app increased HIV self-testing and helped those who tested positive get medical follow-up.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,800 people

The number who actually took part.

Started

Dec 2021

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years or older * Chinese * Cis-gender male * Condomless anal sex with another man in the past 6 months * Resident in the study location for at least 6 months and no desire to relocate during the study period * In possession of a mobile "smart" phone with capability to download and use WeChat * HIV-negative (verified through HIV self-test at enrollment) * Able to give informed consent Exclusion Criteria: * HIV positive at enrollment * Self-report coercion to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease Homosexuality

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

  • Chengdu Tongle Health Counselling Service Center

    Chengdu, Sichuan, China

  • Suzhou Centers for Disease Control and Prevention

    Suzhou, Jiangsu, China

  • Wuhan Centers for Disease Control and Prevention

    Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.